Destiny Pharma's CEO says that one year after listing on the London stock market, the antimicrobial specialist is on track to start the Phase IIb study of its lead asset for the prevention of post-surgical infections early next year and expects that to readout in the second half of 2019.
In an interview with Scrip, Neil Clark also said the group has enough money to then see it into the...








